海翔药业(002099) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥486,432,558.84, a decrease of 7.95% compared to ¥528,463,890.64 in the same period last year[5]. - Net profit attributable to shareholders was ¥9,229,942.41, down 71.68% from ¥32,593,338.56 year-on-year[5]. - Basic earnings per share decreased by 50.00% to ¥0.01 from ¥0.02 in the same period last year[5]. - Net profit for the period was ¥8,313,435.12, down from ¥32,097,804.14, indicating a significant decrease of approximately 74.1% year-over-year[19]. - The total comprehensive income for the period was ¥8,313,435.12, down from ¥32,097,804.14, indicating a decrease of approximately 74.1% year-over-year[20]. - Cash received from sales of goods and services was ¥344,510,881.75, down from ¥363,343,382.36, a decrease of about 5.5% year-over-year[21]. Cash Flow - The net cash flow from operating activities was negative at -¥24,869,922.89, a decline of 187.30% compared to ¥28,489,229.96 in the previous year[5]. - Operating cash inflow totaled $415.84 million, a decrease from $440.57 million in the previous period[22]. - Net cash outflow from operating activities was $24.87 million, compared to a net inflow of $28.49 million previously[22]. - Investment activities generated a net cash inflow of $348.30 million, a significant improvement from a net outflow of $58.75 million last period[22]. - The net increase in cash and cash equivalents was $616.17 million, up from $210.10 million in the prior period[22]. - The ending balance of cash and cash equivalents was $1.55 billion, compared to $1.46 billion at the end of the previous period[22]. Assets and Liabilities - Total assets increased by 1.84% to ¥7,592,942,196.41 from ¥7,456,044,106.37 at the end of the previous year[5]. - Total current assets increased to ¥3,123,540,366.39 from ¥2,890,751,484.57, reflecting a growth of approximately 8.06%[15]. - Total liabilities increased to ¥2,452,798,237.92 from ¥2,324,213,583.00, marking an increase of about 5.5% year-over-year[16]. - Total equity attributable to shareholders increased slightly to ¥5,148,301,694.14 from ¥5,139,071,751.73, reflecting a marginal increase of approximately 0.2% year-over-year[16]. Shareholder Information - Total number of common stock shareholders at the end of the reporting period is 31,964[11]. - Zhejiang Donggang Industrial Co., Ltd. holds 32.37% of shares, totaling 523,982,587 shares, making it the largest shareholder[11]. - The largest shareholder, Wang Yunfu, holds 7.34% of shares, totaling 118,800,000 shares[11]. - The company has repurchased 31,478,531 shares, accounting for 1.94% of the total share capital as of March 31, 2025[12]. Operating Costs and Expenses - Total operating costs increased to ¥466,678,445.96 from ¥452,546,121.15, reflecting an increase of about 3.0% year-over-year[18]. - The company experienced a 41.71% increase in taxes and surcharges, amounting to ¥8,884,372.07 compared to ¥6,269,407.94 in the previous year[9]. - The company reported a 1992.86% increase in other operating expenses, totaling ¥4,103,343.90, primarily due to tax penalties[9]. - Cash paid to employees increased to $94.77 million from $70.85 million, reflecting a rise of approximately 33.8%[22]. - Cash paid for taxes rose to $33.11 million, compared to $27.43 million, marking a 20.6% increase[22]. Investment Income - The company reported a significant increase in investment income, rising by 130.64% to ¥1,846,487.16 from a loss of ¥6,025,573.27 in the previous year[9]. - The net cash flow from investing activities improved significantly, reaching ¥348,300,280.99 compared to -¥58,747,912.25 in the same period last year, an increase of 692.87%[9]. - Cash inflow from other investment activities surged to $388.22 million from $4.62 million, indicating a substantial growth[22]. Research and Development - Research and development expenses remained stable at ¥30,648,501.47 compared to ¥30,007,076.80, showing a slight increase of approximately 2.1% year-over-year[19]. - The company has not disclosed any new product or technology developments in the current reporting period[13].